Exhibit 10.2
Confidential treatment has been
requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request.
Omissions are designated as [***]. A complete version of this
exhibit has been filed separately with the Securities and Exchange
Commission.
FIRST AMENDMENT
TO DEVELOPMENT AND SUPPLY
AGREEMENT
Effective as of date
of the last signature below, Abbott Laboratories, an Illinois
corporation having a principal place of business at 100 Abbott Park
Road, Abbott Park, Illinois 60064-3500 (“Abbott”), and
Seattle Genetics, Inc., a Delaware corporation having a principal
place of business at 21823 – 30 th Drive Southeast in Bothell,
Washington 98021 (“Seattle Genetics”) (individually the
“Party” or collectively the “Parties”)
agree to the following terms and conditions (“First
Amendment”) as set forth below.
WHEREAS, the Parties entered into a Development and
Supply Agreement with an Effective Date of February 18, 2005
for the manufacture of a humanized anti-CD40 S2C6 monoclonal
antibody known as SGN-40 (the “Agreement”);
and
WHEREAS, the Parties have agreed to conduct additional
development and manufacturing work pursuant to the terms and
conditions of the Agreement; and
NOW, THEREFORE,
in consideration of the mutual
covenants and agreements contained here and for other good and
valuable consideration, the receipt and sufficiency of which is
hereby acknowledged, the Parties agree as follows:
1. Incorporation of the
Agreement . All capitalized terms which are used but not
otherwise defined herein shall have the same meanings as set forth
in the Agreement, and the Agreement, to the extent not inconsistent
with this First Amendment, is incorporated herein by this reference
as though the same was set forth in its entirety. To the extent any
terms and provisions of the Agreement are inconsistent with the
amendments set forth in Paragraph 2 below, such terms and
provisions shall be deemed superseded hereby. Except as
specifically set forth herein, the Agreement shall remain in full
force and effect and its provisions shall be binding on the parties
hereto.
2. Additional Clinical
Supplies . The Parties agree that Abbott shall manufacture and
Seattle Genetics shall purchase [ *** ] additional batches
of clinical Bulk Drug Substance as described in Stage 1 of
Attachment 1 hereto in accordance with the terms and conditions of
the Agreement, including the Bulk Drug Substance Specifications set
forth
